Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Iovance Biotherapeutics, Inc.

NASDAQ: IOVA · Life Sciences · 7 alerts · CIK 1425205

Share price
$7.55Close, Nov 16
Market cap
$3.49B
Shares outstanding
462.66MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Iovance Biotherapeutics, Inc. filings on SEC EDGAR ↗

9:16 AM ET 10-Q
Financial Results ▶ Call

Iovance Biotherapeutics Q3 2026 Results: Net Loss of $22.3M, Loss Narrows

Iovance Biotherapeutics reported significant revenue growth for the nine months ended September 30, 2026, reaching $292.2 million compared to $176.7 million in the prior year. The company successfully narrowed its net loss to $148.6 million from $319.1 million, supported by reduced research and development expenses and increased product sales.

Key figure
Net loss $22.3M
7:09 AM ET 8-K
Financial Results

Iovance Biotherapeutics Financial Results

Iovance Biotherapeutics reported record third quarter 2026 total revenue of approximately $122 million, an 80% increase year-over-year, driven by strong demand for its TIL therapy Amtagvi. The company achieved a record gross margin of approximately 60% and reaffirmed its full-year 2026 revenue guidance of $410 million to $420 million.

Term
Q3 2026

“Third quarter revenue reached a new record of ~$122 million with our highest gross margin ever, driven by continued U.S. Amtagvi demand. We remain on track to achieve our full-year 2026 total revenue guidance of $410 to $420 million and recently marked the tremendous milestone of more than 1,000 commercially treated Amtagvi patients.”

Frederick Vogt, Ph.D., J.D., Interim Chief Executive Officer and President

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.